Effects of Zishen Yutai Pills on in vitro Fertilization-Embryo Transfer Outcomes in Patients with Diminished Ovarian Reserve: A Prospective, Open-Labeled, Randomized and Controlled Study.
10.1007/s11655-023-3546-y
- Author:
Xiu-Fang LI
1
;
Zhong-Qing WANG
2
;
Hai-Yan XU
3
;
Hong LIU
3
;
Yan SHENG
3
;
Jin XU
3
;
Yuan-Mei LI
3
;
Fang LIAN
4
,
5
Author Information
1. The First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
2. Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
3. Center for Reproductive Medicine, Shandong University, Jinan, 250021, China.
4. Reproductive and Genetic Center of Integrated Traditional and Western Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China. fang_lian123@
5. com.
- Publication Type:Journal Article
- Keywords:
Zishen Yutai Pills;
diminished ovarian reserve;
embryos;
in vitro fertilization-embryo transfer;
oocytes
- MeSH:
Infant, Newborn;
Pregnancy;
Female;
Humans;
Fertilization in Vitro/methods*;
Ovarian Reserve;
Prospective Studies;
Premature Birth;
Embryo Transfer/methods*;
Ovulation Induction/methods*;
Gonadotropin-Releasing Hormone/therapeutic use*
- From:
Chinese journal of integrative medicine
2023;29(4):291-298
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the effects of Zishen Yutai Pills (ZYPs) on the quality of oocytes and embryos, as well as pregnancy outcomes in patients with diminished ovarian reserve (DOR) receiving in vitro fertilization-embryo transfer (IVF-ET). The possible mechanisms, involving the regulation of bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9), were also investigated.
METHODS:A total of 120 patients with DOR who underwent their IVF-ET cycle were randomly allocated to 2 groups in a 1:1 ratio. The patients in the treatment group (60 cases) received ZYPs from the mid-luteal phase of the former menstrual cycle by using gonadotropin-releasing hormone (GnRH) antagonist protocol. The patients in the control group (60 cases) received the same protocol but without ZYPs. The primary outcomes were the number of oocytes retrieved and high-quality embryos. Secondary outcomes included other oocyte or embryo indices as well as pregnancy outcomes. Adverse events were assessed by comparison of the incidence of ectopic pregnancy, pregnancy complications, pregnancy loss, and preterm birth. Contents of BMP15 and GDF9 in the follicle fluids (FF) were also quantified with enzyme-linked immunosorbent assay.
RESULTS:Compared with the control group, the numbers of oocytes retrieved and high-quality embryos were significantly increased in the ZYPs group (both P<0.05). After treatment with ZYPs, a significant regulation of serum sex hormones was observed, including progesterone and estradiol. Both hormones were up-regulated compared with the control group (P=0.014 and 0.008), respectively. No significant differences were observed with regard to pregnancy outcomes including implantation rates, biochemical pregnancy rates, clinical pregnancy rates, live birth rates, and pregnancy loss rates (all P>0.05). The administration of ZYPs did not increase the incidence of adverse events. The expressions of BMP15 and GDF9 in the ZYPs group were significantly up-regulated compared with the control group (both P<0.05).
CONCLUSIONS:ZYPs exhibited beneficial effects in DOR patients undergoing IVF-ET, resulting in increments of oocytes and embryos, and up-regulation of BMP15 and GDF9 expressions in the FF. However, the effects of ZYPs on pregnancy outcomes should be assessed in clinical trials with larger sample sizes (Trial reqistration No. ChiCTR2100048441).
